Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: Results of a 1-year prospective trial

Retina

Volumn 32, Issue 6, 2012, Pages 1106-1113

  Zhang, Han ^a   Liu, Zhe Li ^a   Sun, Peng ^a   Gu, Feng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Avastin; bevacizumab; choroidal neovascularization; intravitreal injection; punctate inner choroidopathy

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHOROID DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PUNCTATE INNER CHOROIDOPATHY; RECURRENT DISEASE; RETINA; SUBRETINAL NEOVASCULARIZATION; VISION; VISUAL ACUITY;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID DISEASES; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VISUAL ACUITY; YOUNG ADULT;

EID: 84861799183     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318242b9da     Document Type: Article

References (32)

1. Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996; 103:1241-1244.
2. Essex RW, Wong J, Fraser-Bell S, et al. Punctate inner cho-roidopathy: clinical features and outcomes. Arch Ophthalmol 2010;128:982-987.
3. Watzke RC, Packer AJ, Folk JC, et al. Punctate inner choroid-opathy. Am J Ophthalmol 1984;98:572-584.
4. Brown J Jr, Folk JC, Reddy CV, Kimura AE. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology 1996; 103:1100-1105.
5. Gerstenblith AT, Thorne JE, Sobrin L, et al. Punctate inner choroidopathy: a survey analysis of 77 persons. Ophthalmology 2007;114:1201-1204.
6. Kedhar SR, Thorne JE, Wittenberg S, et al. Multifocal choroi-ditis with panuveitis and punctate inner choroidopathy: comparison of clinical characteristics at presentation. Retina 2007; 27:1174-1179.
7. Patel KH, Birnbaum AD, Tessler HH, Goldstein DA. Presentation and outcome of patients with punctate inner choroidopathy at a tertiary referral center. Retina 2011;31:1387-1391.
8. Zhang X, Wen F, Zuo C, et al. Clinical features of punctate inner choroidopathy in Chinese patients. Retina 2011;31: 1680-1691.
9. Brueggeman RM, Noffke AS, Jampol LM. Resolution of punctate inner choroidopathy lesions with oral prednisone therapy. Arch Ophthalmol 2002;120:996.
10. Olsen TW, Capone A Jr, Sternberg P Jr, et al. Subfoveal cho-roidal neovascularization in punctuate inner choroidopathy. Surgical management and pathologic findings. Ophthalmology 1996;103:2061-2069.
11. Postelmans L, Pasteels B, Coquelet P, et al. Severe pigment epithelial alterations in the treatment area following photody-namic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 2004;138:803-808.
12. Bressler NM. Antiangiogenic approaches to age-related macu-lar degeneration today. Ophthalmology 2009;116:S15-S23.
13. Schouten JS, La Heij EC, Webers CA, et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247:1-11.
14. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100.
15. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidop-athy, or of idiopathic origin. Am J Ophthalmol 2007;143:977-983.
16. Mansour AM, Mackensen F, Arevalo JF, et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2008;146:410-416.
17. Mansour AM, Arevalo JF, Ziemssen F, et al. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2009;148:310-316.
18. Spiteri Cornish K, Williams GJ, Gavin MP, Imrie FR. Visual and optical coherence tomography outcomes of intravitreal bevacizumab and ranibizumab in inflammatory choroidal neo-vascularization secondary to punctate inner choroidopathy. Eur J Ophthalmol 2010;21:440-445.
19. Arevalo JF, Adan A, Berrocal MH, et al. Intravitreal bevaci-zumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months. Retina 2011;31:353-363
20. Macular Photocoagulation Study Group. Argon laser photo-coagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991;109: 1109-1114.
21. Flaxel CJ, Owens SL, Mulholland B, et al. The use of cortico-steroids for choroidal neovascularisation in young patients. Eye 1998;12:266-272.
22. Leslie T, Lois N, Christopoulou D, et al. Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression. Br J Ophthalmol 2005;89: 147-150.
23. Coco RM, de Souza CF, Sanabria MR. Photodynamic therapy for subfoveal and juxtafoveal choroidal neovasculariza-tion associated with punctate inner choroidopathy. Ocul Immunol Inflamm 2007;15:27-29.
24. Fong KC, Thomas D, Amin K, et al. Photodynamic therapy combined with systemic corticosteroids for choroidal neovas-cularisation secondary to punctuate inner choroidopathy. Eye 2008;22:528-533.
25. Chan WM, Lai TY, Lau TT, et al. Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovas-cularization secondary to punctate inner choroidopathy or of idiopathic origin: one-year results of a prospective series. Retina 2008;28:71-80.
26. Postelmans L, Pasteels B, Coquelet P, et al. Photodynamic therapy for subfoveal classic choroidal neovascularization related to punctate inner choroidopathy (PIC) or presumed ocular histo-plasmosis-like syndrome (POHS-like). Ocul Immunol Inflamm 2005;13:361-366.
27. Treatment of Age-related Macular Degeneration with Photody-namic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials\TAP report 2. Arch Ophthalmol 2002;119: 198-207.
28. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovasculariza-tion in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial\VIP report no. 1. Ophthalmology 2001;108:841-852.
29. Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001;132:794-796.
30. Shimada H, Yuzawa M, Hirose T, et al. Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy. Jpn J Ophthalmol 2008;52:282-288.
31. Tatar O, Yoeuek E, Szurman P, et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascu-larization. Arch Ophthalmol 2008;126:782-790.
32. Petrou P, Georgalas I, Giavaras G, et al. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthal-mol 2010;88:e136.